Molecular signatures of longevity identify compounds that extendmouse lifespan and healthspan

Shindyapina, A. V., Tyshkovskiy, A., Bozaykut, P., Castro, J. P., Gerashchenko, M. V., Trapp, A., Meer, M. V., Zhang, B., Poganik, J. R., Horvath, S., Miller, R. A., Gladyshev, V. N.

Brigham and Women\'s Hospital, Harvard Medical School, Boston, MA 02115, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA · biorxiv

Paper

Abstract

Longevity interventions in mammals are typically discovered on a case-by-case basis, hindering systematic geroprotector development. We developed a platform for the identification of longevity interventions integrating longevity gene expression biomarkers within and across species, in silico chemical screening, analyses of selected compounds in cell culture, short-term dietary interventions coupled with omics profiling, and ultimately lifespan studies in mice. This approach identified compounds (selumetinib, vorinostat, celastrol, AZD-8055, LY-294002) that extended lifespan and/or healthspan in aged C57BL/6JN male mice, with limited effects in females. In addition, selumetinib and vorinostat increased lifespan when administered to young, genetically heterogeneous UM-HET3 mice. Our biomarker-driven platform accelerates geroprotector discovery, offering a scalable approach to target conserved longevity pathways.

The following analysis is generated by AI and may contain errors. It is separate from the authors’ abstract and is not peer review.

Research summary

The paper claims that a biomarker-driven platform can identify compounds that extend lifespan and healthspan in mice. This research is relevant as it addresses the root causes of aging by discovering geroprotectors that target conserved longevity pathways, rather than merely treating age-related diseases.

Author of this paper? Send a correction.